Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a nearly 100 million yuan Series A+ funding round. The round was led by Xingzheng Capital, with participation from Ji Gao Financial Company and Nanjing Innovation Investment Group. Kaideng Capital continued to serve as the exclusive financial advisor. This funding round has garnered support from renowned investment institutions and local state-owned capital, reflecting their recognition and backing of Milestone Biotechnologies’ growth potential.
Accelerating Development and Global Expansion
The funds raised will be primarily used to accelerate the development of a range of primary cell models, accompanying reagents and consumables, as well as scientific research services. Additionally, the company plans to further expand its overseas business scope and scale, aiming to become a one-stop supplier for the entire industry chain of biomedical cell applications. In 2023, Milestone Biotechnologies secured a Series A funding round exceeding 100 million yuan, led by Zhongke Haichuang, Gao Ling Ventures (GL Ventures), Yida Capital, Shanghai Titan Scientific Co., Ltd. (SHA: 688133), and Kaideng Capital.
Industry Leadership and Innovation
Through years of research and development, Milestone Biotechnologies has become a leader in the primary cell industry, offering leading services and response times. The company has established a nationwide production and sales network and has successfully expanded its business overseas. Since its Series A funding, Milestone Biotechnologies has launched its research and development center at the Zhangjiang Innovation Drug Industrialization Base, providing strong support for the integrated platform of cell model and related reagent consumables research, development, production, and process development.
Expanding Product Portfolio and Market Reach
Building on its leading primary immune cell business, Milestone Biotechnologies has successfully developed new products such as cell cryopreservation solutions and cell culture media. The company has also optimized and developed new animal liver cell products, successfully entering overseas markets. Notably, the Kryogene™ cell therapy cryopreservation solution has been filed with the FDA DMF, and the Kryogene™ cell preservation solution has been successfully registered as a medical device. These products have been adopted by numerous enterprises and academic institutions, expanding their reach into the health and medical fields and broadening the customer base.-Fineline Info & Tech
